GlaxoSmithKline LLC v. Banner Pharmacaps, Inc., No. 13-1593 (Fed. Cir. Feb. 24, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Plaintiff GlaxoSmithKline LLC (“GSK”) sued Banner Pharmacaps, Inc., Impax Laboratories, Inc., R oxane Laboratories, Inc., Mylan Inc., Mylan Ph armaceuticals, Inc., and Wat son Laboratories, Inc. –Florida (collectively, “Defendants”). Invoking 35 U.S.C. § 271(e)(2), GSK alleged that drug products containing the molecule dutas- teride that Defendants propose to market fall within claims of U.S. Patent No. 5,565,467, which covers duta s- teride and its pharmaceutically acceptable solvate s.